Targeting Late Na + Current: Too Late or Better Late Than Never?
- 6 July 2026
- journal article
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 139 (2) , e328633
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Catheter Ablation or Antiarrhythmic Drugs for Ventricular TachycardiaNew England Journal of Medicine, 2025
- Fibroblast growth factor homologous factors: canonical and non‐canonical mechanisms of actionThe Journal of Physiology, 2024
- Contrasting Ionic Mechanisms of Impaired Conduction in FHF1 - and FHF2 -Deficient HeartsCirculation: Arrhythmia and Electrophysiology, 2022
- Fibroblast growth factor homologous factors serve as a molecular rheostat in tuning arrhythmogenic cardiac late sodium currentNature Cardiovascular Research, 2022
- Chamber-enriched gene expression profiles in failing human hearts with reduced ejection fractionScientific Reports, 2021
- Ranolazine in High-Risk Patients With Implanted Cardioverter-DefibrillatorsJACC, 2018
- Ranolazine terminates atrial flutter and fibrillation in a canine modelHeart Rhythm, 2014
- Electrophysiologic basis for the antiarrhythmic actions of ranolazineHeart Rhythm, 2011
- Suppression of Re-Entrant and Multifocal Ventricular Fibrillation by the Late Sodium Current Blocker RanolazineJACC, 2011
- Heart failure enhances susceptibility to arrhythmogenic cardiac alternansHeart Rhythm, 2009